Navigation Links
Ultrasound Transducer Disinfection in Many Cases Insufficient
Date:12/11/2008

HAMBURG, Germany, December 11 /PRNewswire/ --

- New 'Trophon EPR' Device Offers Unique Solution

Current methods of ultrasound transducer disinfection are in many cases not sufficient for clinical practice. This is the latest alarming result issued by the Center for Disease Control and Prevention (CDC), the leading US public health agency, in its recently published Guideline for Disinfection and Sterilization in Healthcare Facilities (1). The guideline is the CDC's response to the rapidly evolving epidemiology of hospital-acquired infections such as Clostridium Difficile (2) or MRSA (3).

In light of this global threat, and with regard to the millions of ultrasound examinations conducted each day, Nanosonics' newest product innovation represents a long-needed milestone in the development of medical devices: due to its unique technology, the Trophon EPR completely satisfies all requirements of the new CDC guideline.

Whereas current methods for high-level disinfection of contaminated transvaginal and transrectal transducers (e.g. aldehydes, alcohol or chlorine) show considerable drawbacks, the Trophon EPR has been custom designed to disinfect intracavity and surface ultrasound transducers, while combining speed, safety and convenience. It delivers high-level disinfection plus (HLD+), including sporicidal efficacy, in only six minutes operating time. The fully automated device can be used directly at the point of care, is easy to operate and is environmentally friendly, leaving water and oxygen as the only by-products.

"We recognised the danger presented by the inadequate disinfection of ultrasound transducers, and know that the Trophon EPR will be indispensable for the urgently needed hygiene necessary in the medical sector, to guarantee the safety of each and every patient", explained David Radford, Director and CEO of Nanosonics Limited, Australia, prior to the impending market launch.

The product technology has been validated by major OEM's (e.g. Philips Healthcare and Siemens Medical Solutions) and dealer commitments have already been approved in several European countries. The European launch of the Trophon EPR is scheduled to start in the first half of 2009. An application for FDA regulatory approval (510k) is on target for lodgement in December 2008, with anticipated approval later in 2009 allowing marketing within North America. For more information about Nanosonics, the Trophon EPR and its platform technology (NanoNebulant(TM)) please visit the Company's websites at http://www.nanosonics.eu and http://www.trophon.com.au.

About Nanosonics

The company is of Australian origin, located in Alexandria, Sydney, with European headquarters in Hamburg, Germany. Nanosonics has been listed on the Australian Securities Exchange (NAN) and Frankfurt Stock Exchange (OQM) since 2007.

The company owns intellectual property relating to unique disinfection and sterilisation technologies, which can be suited to a variety of markets including the healthcare industry, food processing, room and space decontamination, and manufacturing.

Nanosonics is currently focused on developing infection control solutions for the global healthcare market. Initial applications are designed for the reprocessing of reusable medical instruments. The Trophon EPR is specifically designed to disinfect intracavity and surface ultrasound probes. Based on the NanoNebulant(TM) technology it surpasses the limitations of current methods by killing the most resilient micro-organisms, in a fast, safe and convenient way.

(1) Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory Committee. Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008. http://www.cdc.gov/ncidod/dhqp/sterile.html.

(2) Association for Professionals in Infection Control and Epidemiology (APIC). Press release, Orlando, 11 November 2008: Intestinal infection afflicts 13 of 1,000 hospital patients; infection rates 6.5-20 times greater than previous estimates, new study says.

(3) Orsi GB. MRSA: an old and new enemy. Healthcare Infection 2008; 13:73-75.

    World Headquarters
    Nanosonics Ltd.
    Unit 24, 566 Gardeners Road
    Alexandria NSW 2015
    Australia
   http://www.nanosonics.com.au

    European Headquarters
    Nanosonics Europe GmbH
    Falkenried 88, House E
    20251 Hamburg
    Germany
   http://www.nanosonics.eu

    Media Contact Europe
    pluspool GmbH
    Nikola Heimann
    Ballindamm 26
    20095 Hamburg
    Germany
    nikola.heimann@plus-pool.de
    +49-40-35-54-36-24


'/>"/>
SOURCE Nanosonics Europe GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
2. Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
3. MedPro Installs 1000th Ultrasound System Worldwide
4. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
5. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
6. Siemens Showcases New ACUSON S2000 Ultrasound System, as Well as Worlds First Pocket Ultrasound System
7. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
8. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
9. Siemens New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow
10. ALOKA to Introduce New ProSound Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida
11. Memorial Medical First in Stanislaus County to Provide Convertible Ultrasound From ZONARE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading ... today announced that Charles W. Stellar has been named by the WEDI Board of ... January 2016. As an executive leader with more than 35 years of experience in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated ... entrepreneurs, held The Future of San Diego Life Science event at the Estancia La ... community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon and ...
(Date:5/23/2016)... 2016 Oxitec CEO Hadyn Parry ... 10:15 a.m. ET before the United States House Committee on ... can play in controlling the spread of the Aedes ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... self-limiting gene. Trials in Brazil , ...
(Date:5/20/2016)... CA (PRWEB) , ... May 20, 2016 , ... The ... 10 of its most experienced veterinary clients have treated over 100 of their own ... edge technology to provide the highest level of care for their patients. , ...
Breaking Biology Technology:
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/8/2016)...   Valencell , the leading innovator in ... secured $11M in Series D financing. The investment ... fund being launched by UAE-based financial services company ... TDF Ventures and WSJ Joshua Fund. Valencell plans ... growth and accelerate its pioneering innovation in accurate ...
Breaking Biology News(10 mins):